A Phase II, Patient- and Investigator-blinded, Randomized, Placebo-controlled Study to Evaluate Efficacy, Safety and Tolerability of BAF312 (Siponimod) in Patients With Stroke Due to Intracerebral Hemorrhage (ICH)
Latest Information Update: 02 Aug 2021
At a glance
- Drugs Siponimod (Primary) ; Siponimod (Primary)
- Indications Cerebral haemorrhage
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 11 May 2021 Status changed from suspended to completed.
- 30 Apr 2020 Status changed from recruiting to suspended.
- 21 Mar 2020 Planned End Date changed from 30 Nov 2020 to 1 Nov 2021.